Abstract
Among 103 patients with multidrug-resistant HIV who initiated raltegravir, etravirine, and darunavir/ritonavir-containing regimen in the ANRS 139 TRIO trial, 100 participated in extended follow-up and continued study treatment until week 96. Among them, 87 (87%) received an optimized background therapy including either nucleoside reverse transcriptase inhibitors or enfuvirtide, they were 78 (78%) at week 96. At week 96, 88% achieved durable virologic response (<50 copies/mL). CD4 response was maintained (median change of +150 cells/mm(3)). No major toxicity was reported. This triple drug combination showed sustained efficacy and thus should be strongly considered for patients with multiclass-resistant virus.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Darunavir
-
Drug Resistance, Multiple, Viral / drug effects
-
Drug Resistance, Multiple, Viral / genetics
-
Female
-
Follow-Up Studies
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Protease Inhibitors / adverse effects
-
HIV Protease Inhibitors / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Nitriles
-
Pyridazines / administration & dosage
-
Pyridazines / adverse effects
-
Pyrimidines
-
Pyrrolidinones / administration & dosage
-
Pyrrolidinones / adverse effects
-
RNA, Viral / analysis
-
Raltegravir Potassium
-
Ritonavir / administration & dosage
-
Ritonavir / adverse effects
-
Sulfonamides / administration & dosage
-
Sulfonamides / adverse effects
Substances
-
HIV Protease Inhibitors
-
Nitriles
-
Pyridazines
-
Pyrimidines
-
Pyrrolidinones
-
RNA, Viral
-
Sulfonamides
-
etravirine
-
Raltegravir Potassium
-
Ritonavir
-
Darunavir